| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2402641 | Vaccine | 2012 | 9 Pages |
Poliomyelitis is nearing universal eradication; in 2011, there were 650 cases reported globally. When wild polio is eradicated, global oral polio vaccine (OPV) cessation followed by use of universal inactivated polio vaccine (IPV) is believed to be the safest vaccination strategy as IPV does not mutate or run the risk of vaccine derived outbreaks that OPV does. However, IPV is significantly more expensive than OPV. One strategy to make IPV more affordable is to reduce the dose by adding adjuvants, compounds that augment the immune response to the vaccine. No adjuvants are currently utilized in stand-alone IPV; however, several have been explored over the past six decades. From aluminum, used in many licensed vaccines, to newer and more experimental adjuvants such as synthetic DNA, a diverse group of compounds has been assessed with varying strengths and weaknesses. This review summarizes the studies to date evaluating the efficacy and safety of adjuvants used with IPV.
► Adjuvants are an option to reduce the cost and improve the immunogenicity of IPV. ► Since the 1950s, several adjuvants have been explored with IPV. ► No adjuvants are currently used in standalone IPV. ► This review compares published data on different adjuvants and their effectiveness.
